On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
April 21, 2021
- FPMAJ Chief Calls for Uninterrupted Govt Support for Japan-Made Vaccines Even in Ordinary Times
April 20, 2021
- Over 50% of Itraconazole ADR Reporting Comes from Pharmacists in October-December: PMDA
April 20, 2021
- Automatic Listing for Approved Drugs Erodes Financial Predictability: MOF
April 19, 2021
- MHLW to Revoke Approval of 12 Kobayashi Kako Products as Documents Fabricated
April 19, 2021
- Industry Veteran Prods Appropriate Evaluation for Innovation: LDP Confab
April 16, 2021
- Chuikyo Receives Report on Fertility Treatment Survey, Awaits Guidelines to Discuss Coverage
April 16, 2021
- 2 New Payer Members Make Chuikyo Debut
April 15, 2021
- Ultomiris Now Braced for Price Cut as Chuikyo OKs CEA Results
April 15, 2021
- LDP Project Team to Compile Proposal on Japan-Made Vaccine Development
April 15, 2021
- Bayer’s Heart Failure Med Vericiguat Up for 2nd PAFSC Review
April 15, 2021
- MHLW Presents Discussion Timeline for FY2022 Reform
April 15, 2021
- Olumiant Up for PAFSC Review for COVID-19 on April 21, Combo Use with Veklury
April 15, 2021
- Drug Pricing Rules to Be Applied to Breyanzi: Chuikyo
April 15, 2021
- Yescarta to Join NHI Price List on April 21, Gets CEA-Tweak from Get-Go
April 14, 2021
- Kymriah to Get 4.3% Reduction, Trelegy 0.5% Cut in 1st CEA-Based Price Tweak
April 14, 2021
- 11 APIs to Get NHI Price Listing on April 21, 17 Billion Yen Peak Sales Projected for Lilly’s Migraine Med
April 14, 2021
- Novo’s Growth Hormone, Fujimoto’s Hemophilia Med Skip April Listing
April 14, 2021
- Japan to Prioritize Screening for N501Y Variant; E484K “Does Not Render Vaccines Ineffective”: Minister
April 14, 2021
- LDP Pharma Study Group to Discuss R&D Support, Eyes Proposal
April 13, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…